Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2023-04-19 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
第三届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the 15th meeting of the third Supervisory Board of Chengdu Oukang Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and the approval of a proposal to elect a new supervisor due to a resignation. The content focuses on board/management changes and governance procedures, referencing relevant laws and company bylaws. There is no financial data, earnings information, or report publication mentioned. The document is not a full report but an official announcement of board-level decisions regarding management composition. Therefore, it fits best under Board/Management Information (MANG). The document length is short and specific to management changes, confirming this classification with high confidence.
2023-04-19 Chinese
监事辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company supervisor (监事) named Wei Liuli from Chengdu Oukang Pharmaceutical Co., Ltd. It details the resignation date, reasons, impact on the company, and legal compliance. There is no financial data, no mention of financial results, no report publication, no voting results, no capital changes, or other financial or regulatory filings. The content focuses on management changes specifically related to the supervisory board. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is a direct announcement, not a report or certification.
2023-04-17 Chinese
申万宏源证券承销保荐有限责任公司关于成都欧康医药股份有限公司治理专项自查及规范活动的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities underwriting and sponsorship company regarding a special governance self-inspection and compliance activity for Chengdu Oukang Pharmaceutical Co., Ltd. It covers internal system construction, organizational setup, board and senior management qualifications and duties, decision-making procedures, governance constraints, and other compliance matters for the fiscal year 2022. The document is titled as a "special inspection report" and contains substantive content on governance and compliance, not just an announcement or summary. It is not a full annual report or financial statement but a focused audit or inspection report on governance and compliance. This fits the definition of an Audit Report / Information (AR) which includes standalone audit reports and results of internal or regulatory inspections excluding full annual reports. The document length is 3247 characters, which is relatively short but contains detailed substantive content, so it is not a mere announcement. Therefore, the best classification is AR with high confidence.
2023-04-12 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2022' which translates to 'Annual Report 2022'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal controls, and financial accounting reports. The document includes audited financial data, management certifications, and auditor's unqualified opinion, all consistent with a comprehensive annual report. The length is substantial (15,000 characters), and it is not merely an announcement or a brief summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-12 Chinese
成都欧康医药股份有限公司2022年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled "2022年度审计报告" which translates to "2022 Annual Audit Report" for Chengdu Oukang Pharmaceutical Co., Ltd. It contains detailed audit opinions, basis for audit opinions, key audit matters such as revenue recognition and inventory measurement, responsibilities of management and auditors, and detailed consolidated financial statements including balance sheets as of December 31, 2022. The content is consistent with a standalone audit report issued by a certified public accounting firm, focusing on the audit of the financial statements for the fiscal year 2022. It is not an annual report (10-K) because it does not include comprehensive company activity or management discussion and analysis, but rather focuses on the audit opinion and related audit information. It is not a certification or a short announcement but a full audit report document. Therefore, the appropriate classification is Audit Report / Information (AR).
2023-04-12 Chinese
2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Director's Report." It details the independent directors' attendance at board and shareholder meetings, their opinions on various company matters, their efforts to protect investor rights, and their training activities during the year 2022. The content focuses on the independent directors' duties, opinions, and oversight activities rather than financial statements or audit results. It is a report by the board members (independent directors) about their management and supervisory activities over the year. This fits the category of Board/Management Information (MANG), which includes announcements of changes or reports related to the company's board or senior management activities. The document is not an annual report (10-K), audit report (AR), or any other financial report type. The length is under 5,000 characters but the content is substantive and not merely an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is MANG with high confidence.
2023-04-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.